Literature DB >> 11353567

Serum uric acid as a cardiovascular risk factor for heart disease.

M H Alderman1.   

Abstract

Cardiovascular risk factors are those environmental, behavioral, genetic, and/or personal factors whose presence indicates a heightened risk of subsequent vascular disease events. Smoking, hypertension, and hyperlipidemia, initially identified by astute clinicians, were all subsequently confirmed and defined as risk factors through formal prospective epidemiologic study, long before evidence of causality was available. Ultimately, clinical trials demonstrated a reversible contribution of both high blood pressure and elevated lipids to stroke and heart disease. As a result, these risk factors are now the cornerstones for both assessment of relative cardiovascular risk and targets for preventive intervention. The criterion for risk factor status is a strong, consistent, timely, and statistically significant association to disease events that is independent of and unconfounded by other known risk factors. The purpose of this review is to assess available data to determine whether or not serum uric acid meets the standard for designation as a risk factor.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11353567     DOI: 10.1007/s11906-001-0036-4

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  32 in total

1.  Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study.

Authors:  B F Culleton; M G Larson; W B Kannel; D Levy
Journal:  Ann Intern Med       Date:  1999-07-06       Impact factor: 25.391

2.  Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study.

Authors:  P Verdecchia; G Schillaci; G Reboldi; F Santeusanio; C Porcellati; P Brunetti
Journal:  Hypertension       Date:  2000-12       Impact factor: 10.190

3.  Serum uric acid and risk of coronary heart disease: Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  J T Moriarity; A R Folsom; C Iribarren; F J Nieto; W D Rosamond
Journal:  Ann Epidemiol       Date:  2000-04       Impact factor: 3.797

4.  Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension.

Authors:  R Butler; A D Morris; J J Belch; A Hill; A D Struthers
Journal:  Hypertension       Date:  2000-03       Impact factor: 10.190

5.  Serum uric acid and hypertension: the Olivetti heart study.

Authors:  F Jossa; E Farinaro; S Panico; V Krogh; E Celentano; R Galasso; M Mancini; M Trevisan
Journal:  J Hum Hypertens       Date:  1994-09       Impact factor: 3.012

6.  Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo. Blunted response in essential hypertension.

Authors:  L Linder; W Kiowski; F R Bühler; T F Lüscher
Journal:  Circulation       Date:  1990-06       Impact factor: 29.690

7.  Predictors of stroke in middle-aged patients with non-insulin-dependent diabetes.

Authors:  S Lehto; T Rönnemaa; K Pyörälä; M Laakso
Journal:  Stroke       Date:  1996-01       Impact factor: 7.914

8.  Effects of losartan on a background of hydrochlorothiazide in patients with hypertension.

Authors:  B A Soffer; J T Wright; J H Pratt; B Wiens; A I Goldberg; C S Sweet
Journal:  Hypertension       Date:  1995-07       Impact factor: 10.190

9.  Hyperuricaemia and risk of cardiovascular disease and overall death. A 12-year follow-up of participants in the population study of women in Gothenburg, Sweden.

Authors:  C Bengtsson; L Lapidus; C Stendahl; J Waldenström
Journal:  Acta Med Scand       Date:  1988

10.  The relationship of oxidative stress to thrombotic tendency in type 1 diabetic patients with retinopathy.

Authors:  P E Jennings; M McLaren; N A Scott; A R Saniabadi; J J Belch
Journal:  Diabet Med       Date:  1991-11       Impact factor: 4.359

View more
  7 in total

Review 1.  Hyperuricemia, Cardiovascular Disease, and Hypertension.

Authors:  Masanari Kuwabara
Journal:  Pulse (Basel)       Date:  2016-03-12

2.  Hyperuricemia and its related factors in an urban population, Izmir, Turkey.

Authors:  Ismail Sari; Servet Akar; Betul Pakoz; Ali Riza Sisman; Oguz Gurler; Merih Birlik; Fatos Onen; Nurullah Akkoc
Journal:  Rheumatol Int       Date:  2008-12-02       Impact factor: 2.631

3.  Distinct roles of Nox1 and Nox4 in basal and angiotensin II-stimulated superoxide and hydrogen peroxide production.

Authors:  Sergey I Dikalov; Anna E Dikalova; Alfiya T Bikineyeva; Harald H H W Schmidt; David G Harrison; Kathy K Griendling
Journal:  Free Radic Biol Med       Date:  2008-08-16       Impact factor: 7.376

4.  Serum Uric Acid as an Independent Risk Factor for the Presence and Severity of Early-Onset Coronary Artery Disease: A Case-Control Study.

Authors:  Ting-Ting Tian; Hui Li; Sheng-Jie Chen; Qing Wang; Qing-Wu Tian; Bei-Bei Zhang; Jie Zhu; Guo-Wei He; Li-Min Lun; Chao Xuan
Journal:  Dis Markers       Date:  2018-10-23       Impact factor: 3.434

5.  Dynamic changes in purine catabolism in patients with acute coronary syndrome that underwent percutaneous coronary intervention.

Authors:  Olga Visternichan; Seyed Farzad Jalali; Dana Taizhanova; Larissa Muravlyova; Gaukhar Igimbayeva
Journal:  Caspian J Intern Med       Date:  2019

6.  The IDF Definition Is Better Suited for Screening Metabolic Syndrome and Estimating Risks of Diabetes in Asian American Adults: Evidence from NHANES 2011-2016.

Authors:  Lin Zhu; Cody Spence; Jenny Wei Yang; Grace X Ma
Journal:  J Clin Med       Date:  2020-11-28       Impact factor: 4.241

7.  Prevalence of peripheral artery disease (PAD) and factors associated: An epidemiological analysis from the population-based Screening PRE-diabetes and type 2 DIAbetes (SPREDIA-2) study.

Authors:  V Cornejo Del Río; J Mostaza; C Lahoz; V Sánchez-Arroyo; C Sabín; S López; P Patrón; P Fernández-García; B Fernández-Puntero; D Vicent; L Montesano-Sánchez; F García-Iglesias; T González-Alegre; E Estirado; F Laguna; C de Burgos-Lunar; P Gómez-Campelo; J C Abanades-Herranz; J M de Miguel-Yanes; M A Salinero-Fort
Journal:  PLoS One       Date:  2017-10-26       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.